biotech fireworks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	1/16/2003 4:20:44 PM
From: nigel bates	of 7424

Good Lord ! XOMA makes the fireworks thread - 1:03PM XOMA Limited reiterated by Ryan Beck (XOMA) 4.35 +0.38: Ryan Beck & Co considers Genentech comments on Raptiva a positive for XOMA. According to firm, Genentech (during conference call yesterday) projected FDA approval for Raptiva (psoriasis) as early as Q4 of 2003. This would be about a quarter earlier than Ryan Beck had projected. Firm is encouraged by Genentech's guidance on the regulatory process and the pre-launch activities currently in place; believes this has positive implications for XOMA, which will receive 25% of profits from Raptiva sales. Firm reiterates its Outperform rating and 12-month target of $11. Volume today is 951K, or 1.8x avg. (I have to admit that I hold a few - bought, for the first time, just after Christmas. Oh, the shame of it...)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next